Hospital
Mercy Health - Tiffin Hospital LLC
Mercy Health - Tiffin Hospital LLC was paid $12.99M by Medicaid between Jan 2018 and Dec 2024, across 205 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoMERCY HEALTH - TIFFIN HOSPITAL LLC
TIFFIN, OH 44883
TIFFIN, OH 44883
33aNPI1316994734assigned 05/30/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$12.99M
24GClaims356,623
24DCodes billed205
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,358 | $747K | |
| 2019 | 26,310 | $795K | |
| 2020 | 26,210 | $1.09M | |
| 2021 | 33,191 | $1.38M | |
| 2022 | 30,206 | $1.22M | |
| 2023 | 133,000 | $4.68M | |
| 2024incomplete | 84,348 | $3.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 19,698 | 18,039 | $2.33M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 13,940 | 11,545 | $1.74M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 8.0% | 15,291 | 5,082 | $1.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 7,697 | 5,911 | $1.03M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.9% | 7,927 | 2,316 | $635K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 4,819 | 4,538 | $524K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.0% | 1,540 | 830 | $520K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 1,781 | 1,186 | $493K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.5% | 6,259 | 2,235 | $453K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 1,359 | 1,009 | $345K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 1,752 | 997 | $271K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,211 | 1,154 | $209K |
193 more codes
| 80053 | Comprehensive metabolic panel | 1.3% | 17,315 | $168K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 546 | $167K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 3,593 | $166K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 619 | $158K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 2,831 | $157K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 819 | $150K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.0% | 115 | $132K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 700 | $119K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,129 | $118K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,587 | $95K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 511 | $88K |
| G0378 | Hospital observation service, per hour | <1% | 1,096 | $85K |
| 59025 | Fetal non-stress test | <1% | 515 | $82K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,880 | $68K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,188 | $67K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,839 | $64K |
| 80061 | Lipid panel | <1% | 2,538 | $62K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,977 | $61K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 520 | $56K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,101 | $56K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,087 | $51K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,043 | $50K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 183 | $46K |
| 92526 | <1% | 670 | $42K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 390 | $38K |
| 85027 | <1% | 4,556 | $33K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,643 | $30K |
| 93242 | <1% | 383 | $28K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,141 | $28K |
| 97533 | <1% | 362 | $28K | |
| 74018 | <1% | 573 | $28K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,204 | $27K |
| 86900 | <1% | 1,013 | $26K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 178 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,701 | $25K |
| 80074 | <1% | 1,241 | $25K | |
| 86803 | <1% | 764 | $25K | |
| 93017 | <1% | 341 | $24K | |
| 97161 | <1% | 385 | $22K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 801 | $21K |
| 84703 | <1% | 2,623 | $20K | |
| 86780 | <1% | 895 | $20K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 370 | $19K |
| 97014 | <1% | 733 | $19K | |
| 93976 | <1% | 157 | $19K | |
| 84702 | <1% | 984 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,009 | $17K |
| 87070 | <1% | 780 | $17K | |
| 70496 | <1% | 62 | $16K | |
| 86850 | <1% | 1,097 | $16K | |
| 93243 | <1% | 369 | $16K | |
| 81001 | <1% | 12,449 | $13K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,581 | $13K |
| 84484 | <1% | 5,207 | $13K | |
| 84439 | <1% | 966 | $12K | |
| 86140 | <1% | 855 | $12K | |
| 86762 | <1% | 549 | $11K | |
| 82607 | <1% | 627 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 617 | $11K |
| 82728 | <1% | 607 | $11K | |
| 87480 | <1% | 607 | $11K | |
| 86901 | <1% | 1,147 | $10K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 677 | $10K |
| 97166 | <1% | 122 | $10K | |
| 73630 | <1% | 511 | $9K | |
| 87340 | <1% | 689 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,738 | $9K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 207 | $9K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 52 | $9K |
| 83550 | <1% | 677 | $8K | |
| 87522 | Neg quan hep c or qual rna | <1% | 150 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 330 | $8K |
| 87660 | <1% | 607 | $8K | |
| 80320 | <1% | 814 | $8K | |
| 83540 | <1% | 745 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 648 | $7K |
| 97162 | <1% | 166 | $7K | |
| 82746 | <1% | 542 | $7K | |
| 73562 | <1% | 301 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,935 | $7K |
| 87186 | <1% | 665 | $7K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 36 | $6K |
| 87510 | <1% | 607 | $6K | |
| 94664 | <1% | 1,044 | $6K | |
| 86403 | <1% | 304 | $6K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 343 | $6K |
| 73610 | <1% | 359 | $6K | |
| 97113 | <1% | 76 | $6K | |
| 82570 | <1% | 707 | $6K | |
| 80306 | <1% | 301 | $6K | |
| 84460 | <1% | 579 | $5K | |
| 73130 | <1% | 407 | $5K | |
| 76642 | <1% | 53 | $5K | |
| 83880 | <1% | 900 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 365 | $5K |
| 83735 | <1% | 2,333 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,233 | $4K |
| 85652 | <1% | 583 | $4K | |
| 84450 | <1% | 539 | $4K | |
| 83970 | <1% | 109 | $4K | |
| 80076 | <1% | 674 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,610 | $4K |
| 93971 | <1% | 57 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,790 | $3K |
| 83516 | <1% | 188 | $3K | |
| 73030 | <1% | 200 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $3K |
| 85610 | <1% | 1,783 | $3K | |
| 83690 | <1% | 4,565 | $3K | |
| 72100 | <1% | 98 | $3K | |
| 71250 | <1% | 33 | $3K | |
| 87077 | <1% | 297 | $2K | |
| 83605 | <1% | 2,055 | $2K | |
| 73110 | <1% | 167 | $2K | |
| 84146 | <1% | 123 | $2K | |
| 82043 | <1% | 295 | $2K | |
| 82947 | <1% | 1,254 | $2K | |
| 96376 | <1% | 894 | $2K | |
| 82805 | <1% | 42 | $1K | |
| 81003 | <1% | 514 | $1K | |
| 87081 | <1% | 64 | $1K | |
| 82784 | <1% | 115 | $1K | |
| 96367 | <1% | 65 | $1K | |
| 84153 | <1% | 54 | $1K | |
| 51798 | <1% | 71 | $1K | |
| 70498 | <1% | 67 | $978.45 | |
| 84156 | <1% | 258 | $954.31 | |
| 73502 | <1% | 48 | $934.88 | |
| 82248 | <1% | 56 | $932.60 | |
| 83001 | <1% | 51 | $904.40 | |
| 85730 | <1% | 339 | $871.63 | |
| 85379 | <1% | 773 | $860.69 | |
| 87088 | <1% | 99 | $754.31 | |
| 87205 | <1% | 180 | $720.65 | |
| 76830 | Ultrasound, transvaginal | <1% | 31 | $681.19 |
| 81025 | <1% | 1,581 | $617.27 | |
| 84550 | <1% | 152 | $612.37 | |
| 87210 | <1% | 57 | $606.06 | |
| 73590 | <1% | 38 | $597.83 | |
| 87040 | <1% | 703 | $556.87 | |
| 83002 | <1% | 32 | $541.35 | |
| 82565 | <1% | 60 | $461.92 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $364.94 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 87 | $355.59 |
| 80143 | <1% | 533 | $308.04 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 32 | $305.74 |
| 84100 | <1% | 55 | $270.17 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 967 | $267.23 |
| 87807 | <1% | 510 | $259.74 | |
| 82670 | <1% | 14 | $234.52 | |
| 90715 | <1% | 12 | $227.22 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,775 | $212.23 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 721 | $146.25 |
| 84481 | <1% | 16 | $132.06 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,007 | $127.78 |
| 80179 | <1% | 505 | $95.68 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 48 | $91.78 |
| 82533 | <1% | 14 | $79.52 | |
| 82150 | <1% | 61 | $78.98 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,378 | $76.03 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 160 | $74.30 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $59.71 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 111 | $57.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 396 | $54.21 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,695 | $45.48 |
| 94761 | <1% | 756 | $37.29 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 69 | $34.86 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 686 | $32.63 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,865 | $32.19 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,986 | $22.98 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 146 | $20.99 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 623 | $15.86 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 204 | $14.62 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 44 | $5.78 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $4.82 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 842 | $3.96 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 16 | $3.70 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 44 | $1.96 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 243 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 310 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 123 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 104 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 156 | $0.00 |
| C1769 | Guide wire | 0% | 46 | $0.00 |
| 73560 | 0% | 14 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 95 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 56 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 117 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 16 | $0.00 |
| 99152 | 0% | 40 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 154 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 22 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 68 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.